Free Trial
NASDAQ:DOMH

Dominari 4/1/2024 Earnings Report

Dominari logo
$6.42 +0.17 (+2.72%)
As of 08/29/2025 04:00 PM Eastern

Dominari EPS Results

Actual EPS
-$1.28
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Dominari Revenue Results

Actual Revenue
$1.01 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Dominari Announcement Details

Quarter
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Dominari's next earnings date is estimated for Thursday, November 6, 2025, based on past reporting schedules.

Conference Call Resources

Dominari Earnings Headlines

Forget Tesla — This Tiny AI Stock Is Musk’s Real Play
While Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it could transform warfare, robotics, and the global economy. But you don’t need to buy Tesla or wait for xAI to IPO to benefit. One overlooked public company is supplying the critical tech behind Musk’s AI push — and it trades for a fraction of Nvidia’s price. Hedge funds are already loading up, but most investors haven’t noticed yet.tc pixel
Dominari Holdings Featured in The Wall Street Journal
See More Dominari Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Dominari? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Dominari and other key companies, straight to your email.

About Dominari

Dominari (NASDAQ:DOMH), a biotechnology company, focuses on developing small-molecule anticancer therapeutics. The company's pipeline of therapeutics includes therapies for prostate cancer, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia. It is developing DHA-dFdC, a pancreatic drug candidate; and KPC34, a small molecule treatment for acute myeloid leukemia and acute lymphoblastic leukemia. The company is also developing an antiviral platform that inhibits replication of viruses, including influenza virus, Ebolavirus and Marburg virus, SARS-CoV, MERS-CoV, and SARS-CoV-2. It has license agreements with the University of Texas, Silo Pharma Inc., and Wake Forest University Health Sciences. The company was formerly known as AIkido Pharma Inc. and changed its name to Dominari Holdings Inc. in December 2022. Dominari Holdings Inc. was founded in 1967 and is headquartered in New York, New York.

View Dominari Profile

More Earnings Resources from MarketBeat